David Warren Carter
Gründer bei DaCart, Inc.
Profil
David Warren Carter is the founder of DaCart, Inc. (founded in 2006) and currently holds the title of President.
He previously held the position of Chairman, President & Chief Executive Officer at Somatix Therapy Corp.
from 1991 to 1997.
From 1997 to 2006, he served as Chairman & Chief Executive Officer at Xenogen Corp.
In 2010, he briefly served as Chief Executive Officer at Origen Therapeutics, Inc. Additionally, he held the position of Director at Cell Genesys, Inc. from 1997 to 2009 and Lead Director at ImmunoGen, Inc. from 1997 to 2011.
He also served as an Independent Director at ThermoGenesis Holdings, Inc. from 2010 to 2013 and as a Director at Caliper Life Sciences, Inc. from 2006 to 2011.
Furthermore, he held the position of Director at Ceregene, Inc. from 2001 to 2004.
He has also served as a Director at Cobalt Technologies, Inc. and as President & Chief Operating Officer at Northfield Laboratories, Inc. He started his career as Vice President-Public Relations at Aetna, Inc. Mr. Carter obtained his undergraduate degree and an MBA from Indiana University.
Aktive Positionen von David Warren Carter
| Unternehmen | Position | Beginn |
|---|---|---|
| DaCart, Inc. | Gründer | 08.10.2009 |
Ehemalige bekannte Positionen von David Warren Carter
| Unternehmen | Position | Ende |
|---|---|---|
| THERMOGENESIS HOLDINGS, INC. | Vorsitzender | 26.09.2012 |
| IMMUNOGEN, INC. | Direktor/Vorstandsmitglied | 08.11.2011 |
Caliper Life Sciences, Inc.
 Caliper Life Sciences, Inc. SemiconductorsElectronic Technology Caliper Life Sciences, Inc. develops, manufactures, and sells labchip systems. It offers microfluids, lab automation, liquid handling, optical imaging technologies, and discovery and development outsourcing solutions. The company was founded by Michael R. Knapp on July 26, 1995 and is headquartered in Hopkinton, MA. | Direktor/Vorstandsmitglied | 07.11.2011 |
Cell Genesys, Inc.
 Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Direktor/Vorstandsmitglied | 14.10.2009 |
Xenogen Corp.
 Xenogen Corp. Medical SpecialtiesHealth Technology Xenogen Corp. provides real time in-vivo imaging services and genetic modification technologies. Its products and technologies include an imaging system, software, and biological materials. Its solutions are designed to improve discovery and pre-clinical research in multiple therapeutic areas. The company was founded by Pamela Reilly Contag and Christopher H. Contag in 1995 and is headquartered in Alameda, CA. | Vorsitzender | 01.08.2006 |
Ausbildung von David Warren Carter
| Indiana University | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| IMMUNOGEN, INC. | Health Technology |
| THERMOGENESIS HOLDINGS, INC. | Health Technology |
| Private Unternehmen | 10 |
|---|---|
Xenogen Corp.
Xenogen Corp. Medical SpecialtiesHealth Technology Xenogen Corp. provides real time in-vivo imaging services and genetic modification technologies. Its products and technologies include an imaging system, software, and biological materials. Its solutions are designed to improve discovery and pre-clinical research in multiple therapeutic areas. The company was founded by Pamela Reilly Contag and Christopher H. Contag in 1995 and is headquartered in Alameda, CA. | Health Technology |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Health Technology |
Aetna, Inc.
 Aetna, Inc. Managed Health CareHealth Services Aetna, Inc. engages in the provision of traditional, voluntary, and consumer-directed health insurance products and related services. It offers benefits, products and services to individuals, employers, healthcare professionals, and producers. The company was founded by Eliphalet Adams Bulkeley in 1853 and is headquartered in Hartford, CT. | Health Services |
Caliper Life Sciences, Inc.
Caliper Life Sciences, Inc. SemiconductorsElectronic Technology Caliper Life Sciences, Inc. develops, manufactures, and sells labchip systems. It offers microfluids, lab automation, liquid handling, optical imaging technologies, and discovery and development outsourcing solutions. The company was founded by Michael R. Knapp on July 26, 1995 and is headquartered in Hopkinton, MA. | Electronic Technology |
| DaCart, Inc. | |
Somatix Therapy Corp.
 Somatix Therapy Corp. BiotechnologyHealth Technology Somatix Therapy Corp. researches, develops, and commercialize proprietary processes for the genetic modification of cells and their use in the treatment of human disease. Somatix's assets include its highly efficient gene transfer technology, broad-based intellectual property, and focused product development programs. The company's most advanced clinical development program, the GVAX cancer vaccine, is in Phase I/II clinical trials for the treatment of metastatic renal cell carcinoma, advanced melanoma, and prostate cancer. It is located in Alameda, CA | Health Technology |
Origen Therapeutics, Inc.
 Origen Therapeutics, Inc. BiotechnologyHealth Technology Origen Therapeutics, Inc. is a biotechnology firm. It develops products from ots avian transgenic platform. The company was founded on April 22, 1997 and is headquartered in Emeryville, CA. | Health Technology |
Northfield Laboratories, Inc.
 Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | Health Technology |
Ceregene, Inc.
 Ceregene, Inc. Pharmaceuticals: MajorHealth Technology Ceregene, Inc. develops pharmaceutical products for neurodegenerative disorders. The company was founded in January 2001 and it is headquartered in Richmond, CA. | Health Technology |
Cobalt Technologies, Inc.
 Cobalt Technologies, Inc. Chemicals: SpecialtyProcess Industries Cobalt Technologies, Inc. develops, produces and commercializes bio-based chemicals. The firm engages in the creation of biobutanol using various cellulosic feedstocks, which include corn cobs, treetops and limbs and dead pine trees from pine beetles. It extracts fermentable sugars from biomass and converts them directly into bio n-butanol, which is an ingredient in coatings, paints, adhesives, sealants, inks and other solvent products. The company was founded by Pamela Reilly Contag in 2005 and is headquartered in Mountain View, CA. | Process Industries |
